Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (196)	3/17/2002 12:45:07 AM
From: tuck	Read Replies (1) \| Respond to of 897

Exubera side effects, got it. Courtesy of the Voice of the Diabetic: >>Pfizer's Exubera inhalable insulin has been in clinicals, and the company was intending to file for FDA approval later this year. That is now on hold. Exubera, intended for use with devices manufactured by Inhale Therapeutics, works, it lowers blood sugars efficiently and consistently—but it has shown some side effects, like a 4x increase in antibodies against insulin, and one case of lung scarring. Accordingly, Pfizer has announced it will delay filing its marketing approval application, and try to solve these problems first.<< Must be the lung scarring that's the big concern. Pfizer has said it would conclude a long term study this year and file the NDA thereafter. It also claimed to know that patients in the trial had pre-existing fibrosis. Sorry, rkrw, should have dug a little harder before pestering you. Cheers, Tuck